Tag Archives: Mayank Mamtani
Intercept Pharma (ICPT) Receives a Buy from B.Riley FBR
In a report released yesterday, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Intercept Pharma (ICPT – Research Report). The company’s shares closed yesterday at $117.34. Mamtani commented: “Sciences, Inc. announced negative results from their Ph. III STELLAR-4
B.Riley FBR Remains a Buy on Arrowhead Research (ARWR)
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Research (ARWR – Research Report) today and set a price target of $19. The company’s shares closed on Friday at $15.66. Mamtani said: “Inc (ARWR) reported fiscal 1Q19 (calendar
